Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Clinical Therapy & Diagnosis (includes Phase 2, Phase 3, post approval studies) - GU

Effect of Bone Marrow Disease on Hematologic Toxicity and PSA Response to 177Lu-PSMA-617 Therapy

Meryam Losee, Nuno Borges Ribeiro Vaz, Mofei Liu, Su Chun Cheng, Arda Konik, Jolivette Ritzer, Andrew Wolanski, Thomas Ng, Atish Choudhury, Mary-Ellen Taplin, Praful Ravi and Heather Jacene
Journal of Nuclear Medicine June 2024, 65 (supplement 2) 241590;
Meryam Losee
1George Washington University
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nuno Borges Ribeiro Vaz
2Brigham and Women's Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mofei Liu
3Dana-Farber Cancer Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Su Chun Cheng
4DFCI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arda Konik
4DFCI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jolivette Ritzer
5Dana Farber Cancer Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Wolanski
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Ng
6Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Atish Choudhury
3Dana-Farber Cancer Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary-Ellen Taplin
3Dana-Farber Cancer Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Praful Ravi
5Dana Farber Cancer Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heather Jacene
3Dana-Farber Cancer Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Article Information

vol. 65 no. supplement 2 241590

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online June 9, 2024.

Copyright & Usage 
© 2024

Author Information

  1. Meryam Losee1,
  2. Nuno Borges Ribeiro Vaz2,
  3. Mofei Liu3,
  4. Su Chun Cheng4,
  5. Arda Konik4,
  6. Jolivette Ritzer5,
  7. Andrew Wolanski,
  8. Thomas Ng6,
  9. Atish Choudhury3,
  10. Mary-Ellen Taplin3,
  11. Praful Ravi5 and
  12. Heather Jacene3
  1. 1George Washington University
  2. 2Brigham and Women's Hospital
  3. 3Dana-Farber Cancer Institute
  4. 4DFCI
  5. 5Dana Farber Cancer Institute
  6. 6Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: June 2024 to April 2025

AbstractFullPdf
Jun 20243800
Jul 202413700
Aug 202410200
Sep 20244300
Oct 20243200
Nov 20246000
Dec 20244600
Jan 20257700
Feb 20256300
Mar 20254000
Apr 20256300
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 65, Issue supplement 2
June 1, 2024
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Effect of Bone Marrow Disease on Hematologic Toxicity and PSA Response to 177Lu-PSMA-617 Therapy
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Effect of Bone Marrow Disease on Hematologic Toxicity and PSA Response to 177Lu-PSMA-617 Therapy
Meryam Losee, Nuno Borges Ribeiro Vaz, Mofei Liu, Su Chun Cheng, Arda Konik, Jolivette Ritzer, Andrew Wolanski, Thomas Ng, Atish Choudhury, Mary-Ellen Taplin, Praful Ravi, Heather Jacene
Journal of Nuclear Medicine Jun 2024, 65 (supplement 2) 241590;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Effect of Bone Marrow Disease on Hematologic Toxicity and PSA Response to 177Lu-PSMA-617 Therapy
Meryam Losee, Nuno Borges Ribeiro Vaz, Mofei Liu, Su Chun Cheng, Arda Konik, Jolivette Ritzer, Andrew Wolanski, Thomas Ng, Atish Choudhury, Mary-Ellen Taplin, Praful Ravi, Heather Jacene
Journal of Nuclear Medicine Jun 2024, 65 (supplement 2) 241590;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy
  • Google Scholar

More in this TOC Section

  • Clinical relevance of post-therapy SPECT/CT in prostate cancer patients treated with Lutetium Lu 177 vipivotide tetraxetan
  • Is it feasible to perform radiopharmaceutical therapies in patients with dialyses: Experience from a comprehensive cancer center in Germany
  • Clinical Phenotype and Outcomes of mCRPC Patients Resistant to 225Ac-PSMA Radioligand Therapy: Analysis of the WARMTH Act Multinational Study
Show more Oncology: Clinical Therapy & Diagnosis (includes Phase 2, Phase 3, post approval studies) - GU

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire